BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$80.69 USD
-0.16 (-0.20%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $80.80 +0.11 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 741 - 760 ( 814 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Catalysts for May and Rest of 2012 for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials: Choppy Aldurazyme Revenue and High R&D Expense Caused a Miss
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q1 Preview: We See at Least an In-Line Quarter due to Booking a Delayed Naglazyme Order
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
GALNS Phase 3 Trial Fully Enrolled. Data Release In Q4 On Schedule. Reiterate NEUTRAL And Fair Value Of $35.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY:11 Financials: Choppy Sales & High Operating Expenses Caused A Miss But We Believe
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q4 Preview: We See a Potential Miss Due To a Delayed Naglazyme Order But Growth Remains Intact. Reiterating NEUTRAL and $35 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of February 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Activation of BMN-111 Program In Achondroplasia Starts Development Timeline.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Corporate Update: Pipeline Investment Supports Long-Term Growth Despite High R&D Impacting 2012 Bottom Line
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L